# **COVID-19 Impact across the Patient Pathway - Incidence and Survival of cancer**

A comparison between April-December 2020 and April-December 2018-2019









#### Coronavirus: New regulations come into force

() 28 March 2020

<



uncertainty fear isolation tracing social wfh lockdowns advice restrictions staffing gp-access stay-at screening hospitals

disruption home

hospitals hsc contact testing

COVID-19

How to



REUTERS\* Word & Business & Markets & Sustainability & Legal & Breakingviews Technology Healthcare & Pharmaceuticals

Northern Ireland to enter six-week

COVID-19 lockdown on Dec. 26 Aa

December 17, 2020 7:52 PM GMT - Updated 2 years ago



General view of The George Best Hotel in Befrast, after It went into administration without ever opening i doors, following the outbreak of the coronavirus disease (COVID-19), Belfast, Northern Ireland, April 29, 2020. REUTERS/Jason Cainduff

#### What are Northern Ireland's new coronavirus restrictions?

- Closure of all non-essential retail
- Closure of close contact services
- Hospitality only permitted to offer takeaway services
- All leisure and entertainment to close (including gyms and pools)
- Off-licences can remain open to 20:00
- Closure of places of worship (except for weddings and funerals)
- Schools to stay open

Restrictions come into force at 00.01 on Friday 27 November 2020







devention on the App Store



Cases in 2018 - 2019

▶ 11.0% decrease - males

During April-Dec - cases

14.4% decrease - females

## **COVID-19 Impact - Cancer cases**

**Public Health** HSC **JNIVERSI** Agency

Cases in 2020



## **COVID-19 Impact - by Age at diagnosis**

- Aged <55yrs .. decreased by 18.6%
- Aged 75+ .. decreased by 7.7% (2,617 to 2,416).

Change in case distribution
 by age statistically
 significant (p = 0.020).



- Impact of screening pause (cervical, breast)
- "ignoring" mild-moderate symptoms
- Major life disruption (WFH, home schooling, childcare etc.)

Apr-Dec period only



## **COVID-19 Impact - by Deprivation quintile**

- Among residents of the least deprived areas ...21.8% decrease.
- Among residents of the most deprived areas ..cases decreased by 7.4%.
- Change by deprivation quintile
   ..statistically significant (p = 0.003).



- Impact of screening pause attendance ↑Less deprived
- ? Interpret STAY AT HOME v strictly Avoid HSC
- Mild-moderate symptoms

Apr-Dec period only







## **COVID-19 Impact - by Cancer type**





#### **COVID-19 Impact - by Method of Hospital Admission**

Proportion of cases with **Emergency Admission increased** by from 15.7% (1,212) to 19.5% (1, 315).

Change in case distribution (by hospital admission type) ... statistically significant (p < 0.001)



Agency

Apr-Dec period only





#### **COVID-19 Impact - by Basis of diagnosis**

 Proportion of cases diagnosed pathologically decreased from 85.1% (6,574) to 82.8% (5,585).

Change in case distribution (by basis of diagnosis) .. statistically significant (p < 0.001)</li>



Apr-Dec period only

#### **Cancers detected by Screening**



- Impact on n/proportion diagnosed via screening
- Impact on early diagnosis (esp Stage 1)





HSC Public Health Agency Cancer Screening Team

- Routine Breast cancer screening ...temporarily paused for four months in 2020...
- Bowel cancer screening programme .. paused in March 2020. Screening colonoscopy services reintroduced by Trusts from June 2020...those who had a positive screening result ...Routine invitations for bowel cancer screening started again from 17<sup>th</sup> August 2020...
- Cervical cancer screening paused 16<sup>th</sup> March 2020 ... programme resumed in June 2020... higher risk prioritised. Routine invitations resumed in August 2020...with catch up..

# Stage shift - from early to more advanced disease

- Proportion of cancers diagnosed at Stage I (Early stage) decreased from 29.3% to 25.1% ..e.g. Screening paused
- Proportion diagnosed at Stage IV (Late stage) increased from 20.5% to 23.2% ...major change to HSC access + behavioral aspects (fear, uncertainty)
- Change in case distribution by stage was statistically significant (p < 0.001).</li>





Apr-Dec period only



#### Impact on treatment

Between 2018-19 and 2020 significant drop in the proportion receiving surgery and radiotherapy.. **↓**Access to Surgery / Radiotherapy...transmission risk / staffing

BUT - no significant change in the **proportion receiving** chemotherapy or hormone therapy..easier to deliver within COVID-19 IPC frameworks

-

Significant increase in % getting No Treatment (29% to 33.4%)..Stage shift + restricted treatment access



HSC

Agency





#### COVID-19 Impact - Survival (Observed), All cancers



**Observed survival (Death from any cause)** 

 Survival one-year after diagnosis decreased from 73.7% to 69.8% (comparing those diagnosed Apr-Dec 2018 - 2019 to Apr-Dec 2020)

 A statistically significant difference existed between the survival curves for 2018-2019 and 2020 (p<0.001).</li>

## COVID-19 Impact - Survival (Net), All cancers



#### Net survival (Cancer related death)

One-year Age-Standardised Net Survival (ASNS) decreased from 76.1% to 72.9%. (comparing those diagnosed Apr-Dec 2018 - 2019 to Apr-Dec 2020)

This change was statistically significant.



#### **COVID-19 Impact - Observed survival**



#### Lung cancer (Significant decrease, p=0.002)



	2018-2019	2020
6 months	56.7% (54.5% - 58.9%)	48.9% (45.7% - 52.1%)
One-year	40.3% (38.1% - 42.4%)	35.0% (32.0% - 38.1%)

#### Prostate cancer (No Significant Change Overall)

Agency



survtime	2018-2019	2020
6 months	97.0% (96.2% - 97.7%)	94.8% (93.2% - 96.1%)
One-year	93.7% (92.5% - 94.7%)	92.8% (90.9% - 94.3%)

#### **COVID-19 Impact - Observed survival**

#### Breast cancer (No Significant Change Overall)



	2018-2019	2020
months	97.4% (96.6% - 98.0%)	96.6% (95.2% - 97.6%)
)ne-year	95.0% (94.0% - 95.9%)	94.6% (92.9% - 95.9%)

	2018-2019	2020
6 months	82.7% (80.8% - 84.4%)	82.3% (79.4% - 84.8%)
One-year	75.2% (73.2% - 77.2%)	77.0% (73.8% - 79.8%)

#### Colorectal cancer (No Significant Change Overall)

Agency





#### Significant decrease

- Head and neck cancer
- Oesophageal cancer
- Lung cancer
- Uterine cancer
- Lymphoma

#### No significant change

- Stomach cancer
- Pancreatic cancer
- Colorectal cancer
- Liver cancer
- Melanoma
- Breast cancer
- Cervical cancer

Ovarian cancer

HSC Agency

- Prostate cancer
- Kidney cancer
- Bladder cancer
- ► Brain cancer
- Myeloma
- Leukaemia







# Summary - profound impact of COVID-19

Cases 13% .....~1000 "missing" cancer cases

Profound impact across the entire cancer patient pathway:

- Presentation **1** emergency admission
- Stage shift from early to more advanced stage disease
- Treatment I surgery and radiotherapy
- Survival Significant reduction one year survival

Need to monitor key cancer statistics to assess for recovery. Also trends in pathologically diagnosed cancers ..recently shown some signs of recovery

# Recent trends in pathologically diagnosed cancers









## Recent trends in patients with Pathologically Diagnosed (PD) cancers: up to March 2023

- Patients with pathology samples indicating cancer (Pathologically Diagnosed (PD)) - to March 2023
- Trends compared with expected levels (annual average patients with PD cancer during 2017-2019) to provide an early signal/indication of COVID-19 impact.
- Data from 4 HSC Pathology Laboratories (Belfast, Antrim, Craigavon, Altnagelvin) - usually monthly.

## **Trend in patients with Pathologically Diagnosed (PD) cancer**





From Mar-20 to Mar-23 number of PD patients -2.8% lower than equivalent period average 2017-2019.

HSC

Agency

NB - some of these "missing" patients may have a clinical only diagnosis (e.g. as a result of an emergency hospital admission) - **need** final registered data.

## Trends in patients with PD cancers - tumour type/age/sex

Compared to expected levels based upon 2017-2019 data, from Mar-20 to Mar-23 -

Largest decreases in PD:

Lung cancers - 18.5%

#### Also

- Males > Females
- ► Younger  $\leq$  69 yrs > Older  $\geq$  70 yrs



**Public Health** 

Agency

JNIVERSIT

# Trends in patients with PD cancers - Lung Cancer



Percentage change from March 2020 to March 2023 compared to expected number based on 2017-2019 average

**Public Health** 

Agency

JEEN'S

JNIVERSIT

**FI FAST** 

ancer

-18.5%







Number of patients with PD lung cancer - increased by 10.1% (first time since pandemic began)

... early signs - turning the corner?







#### Trends in PD patients - more recent weeks (12 weeks to 1<sup>st</sup> Apr 2023)



5.4% <u>increase</u> in PD patients in 12 weeks up to 01-April-23 compared to equivalent weeks in 2017-2019





## **Consequences of reductions in** pathological diagnoses

Patients missed altogether

- Death before cancer diagnosis - from cancer or non-cancer cause (e.g. COVID-19 ... if no health service contact
- Patient living, unaware of cancer.

- Patients diagnosed clinically
  - Patients still diagnosed but likely:
    - Later stage
    - Less likely to receive curative treatment

Agency

Poorer survival outcome



## **Cancer Awareness**



#### Talk to your GP, not yourself.

lealth and

iocial Care

Noticed a change that's unusual for you? Contact your GP practice.

Finding cancer early saves lives.

For more information visit cruk.org/spot-cancer-early-NI







Cancer Research UK is a registered charity in Tingland and Wates (0089464) and Scotland (SCO49666). Also operating in Northern reland,

